Published: July 8, 2022 | Tags: Bausch + Lomb, Novaliq, NOV03, perfluorohexyloctane, Dry Eye Disease, Meibomian Gland Dysfunction, Regulatory, US, FDA, NDA
ADC Entered into an Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in EU and Select International Territories
Published: July 8, 2022 | Tags: ADC, Sobi, Zynlonta, loncastuximab tesirine-lpyl, Pharma EU, International Territories
EarlySign Collaborated with Roche to Develop AI Solution for Early Detection of Lung Cancer
Published: July 8, 2022 | Tags: EarlySign, Roche, AI Solution, Lung Cancer, Pharma, LungFlag
Alvotech Initiates (ALVOEYE) Clinical Study of AVT06, a Proposed Biosimilar to Eylea for Eye Disorders
Published: July 8, 2022 | Tags: Alvotech, AVT06, Biosimilar, Eylea, Eye Disorders, Clinical Trial, ALVOEYE Clinical Study,
Portage Acquires Tarus and Adds Four Adenosine Products to its Pipeline
Published: July 8, 2022 | Tags: Portage, Tarus, PORT-6, PORT-7, PORT-8, PORT-9, Acquire
SD Biosensor and SJL Partners Entered into a Definitive Merger Agreement to Acquire Meridian for ~$1.53B
Published: July 8, 2022 | Tags: SD Biosensor, SJL, Meridian, M&A, ~$1.53B, Consortium, Acquire
Lysogene Presents Preliminary Results of LYS-SAF302 in P-II/III (AAVance) Trial for the Treatment of MPS IIIA in Children at ADVANCE 2022
Published: July 7, 2022 | Tags: Lysogene, LYS-SAF302, MPS IIIA, Clinical Trial, P-II/III, AAVance Trial, ADVANCE, 2022
BeiGene Collaborated with InnoRNA to Discover Novel mRNA-LNP Therapies
Published: July 7, 2022 | Tags: BeiGene, InnoRNA, Novel mRNA Therapies, Pharma
Calithera Reports the First Patient Enrollment of Sapanisertib in P-II Clinical Trial for NRF2-Mutated Squamous Non-Small Cell Lung Cancer
Published: July 7, 2022 | Tags: Calithera, Sapanisertib, NRF2-Mutated, Squamous, Non-Small Cell Lung Cancer, P-II Clinical Trial
Exelixis Entered into an Exclusive License Agreement with Ryvu to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Published: July 7, 2022 | Tags: Exelixis, Ryvu, Novel STING Agonist-Based Targeted, Cancer, Therapies, Pharma
Brii Biosciences Launches Amubarvimab/Romlusevimab Combination in China for the Treatment of COVID-19
Published: July 7, 2022 | Tags: Brii Biosciences, Amubarvimab, Romlusevimab, Pharma, COVID-19, China, P-III, ACTIV-2
DiaMedica Reports the US FDA’s Clinical Hold on the P-II/III (ReMEDy2) Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: July 7, 2022 | Tags: DiaMedica, DM199, Acute Ischemic Stroke, Regulatory, US, FDA, P-II/II, ReMEDy1, ReMEDy2
Nordic Nanovector to Discontinue P-IIb (PARADIGME) Trial of Betalutin in 3L Treatment of Relapsed and Anti-CD20 Refractory Follicular Lymphoma
Published: July 6, 2022 | Tags: Nordic Nanovector, Betalutin, Follicular Lymphoma, Clinical Trial, P-IIb, PARADIGME Trial,
BioArctic Partner Eisai Report the US FDA Acceptance of BLA for Lecanemab to Treat Alzheimer’s Disease
Published: July 6, 2022 | Tags: BioArctic, Eisai, Lecanemab, Alzheimer’s Disease, US, FDA, BLA
Urovant Entered into an Exclusive License Agreement with Pierre Fabre Médicament to Commercialize Vibegron for Overactive Bladder
Published: July 6, 2022 | Tags: Urovant, Pierre Fabre Médicament, Vibegron, Overactive Bladder, Pharma
Genentech Reports the US FDA Acceptance of BLA and Granted Priority Review of Mosunetuzumab for Relapsed or Refractory Follicular Lymphoma
Published: July 6, 2022 | Tags: Genentech, Mosunetuzumab, Follicular Lymphoma, US, FDA, BLA, Priority Review
Sanofi Signs an Exclusive Worldwide Collaboration Agreement with Skyhawk to Discover Novel Small Molecules for Oncology and Immunology Targets
Published: July 6, 2022 | Tags: Sanofi, Skyhawk, Novel Small Molecules, Oncology, Immunology, Pharma, SkySTAR Platform
AstraZeneca to Acquire TeneoTwo for ~$1.27B
Published: July 6, 2022 | Tags: AstraZeneca, TeneoTwo, TNB-486, Calquence, acalabrutinib, B-Cell Haematologic Malignancies, ~$1.27B, Acquire
Astellas Entered into a Research Agreement with Mogrify for In Vivo Regenerative Therapy in Sensorineural Hearing Loss
Published: July 5, 2022 | Tags: Astellas, Mogrify, Sensorineural Hearing Loss, In Vivo Regenerative Therapy, Biotech
EditForce Entered into a License Agreement with Mitsubishi Tanabe Pharma to Develop and Commercialize Gene Therapies for Central Nervous System
Published: July 5, 2022 | Tags: EditForce, Mitsubishi Tanabe Pharma, Gene Therapies, Central Nervous System, Biotech, PPR Protein Platform Technology
Livemetric Receives the US FDA’s Clearance for LiveOne Blood Pressure Monitoring Technology
Published: July 5, 2022 | Tags: Livemetric, LiveOne, Blood Pressure Monitoring Technology, Hypertension, Cardiovascular Diseases, Regulatory, US, FDA, Clearance
Pfizer’s Cibinqo (abrocitinib) Receives Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis
Published: July 5, 2022 | Tags: Pfizer, Cibinqo, abrocitinib, Atopic Dermatitis, Regulatory, Health Canada, Approval
JW Therapeutics Reports Initiation of P-I clinical study for JWATM204 to Treat Advanced Hepatocellular Carcinoma
Published: July 5, 2022 | Tags: JW Therapeutics, JWATM204, Advanced Hepatocellular Carcinoma, Clinical Trial, P-I clinical study
Arctic Vision Reports the First Patient Enrollment in P-III Clinical Trial of ARVN003 for the Treatment of Presbyopia
Published: July 5, 2022 | Tags: Arctic Vision, ARVN003, Presbyopia, Clinical Trial, P-III Clinical Trial, VISION-1, MicroLine
Abbisko Therapeutics Reports the Completion of First Patient Dosing of ABSK061 in P-I (ABSK061-101) Clinical Trial for the Treatment of Solid Tumors
Published: July 4, 2022 | Tags: Abbisko Therapeutics, ABSK061, Solid Tumors, Clinical Trial, P-I, ABSK061-101
Oxford Biomedica Signs Three Year Master Services & Development Agreement with Astrazeneca to Manufacture COVID-19 Vaccines
Published: July 4, 2022 | Tags: Oxford Biomedica, Astrazeneca, COVID-19 Vaccines, Master Services, Pharma, COVID-19 Development Agreement
Nurix Therapeutics Receives the US FDA’s IND Clearance for NX-1607 to Treat Advanced Malignancies
Published: July 4, 2022 | Tags: Nurix Therapeutics, US FDA, IND, Clearance, NX-1607, Advanced Malignancies
Innovent Reports the First Patient Dosing of IBI112 in a P-II Clinical Study for the Treatment of Moderate-to-Severe Active Ulcerative Colitis
Published: July 4, 2022 | Tags: Innovent, IBI112, Active Ulcerative Colitis, Clinical Trial, P-II, Clinical study
Seagen Presents Results of Tukysa (tucatinib) + Trastuzumab in P-II (MOUNTAINEER) Trial for HER2-Positive Metastatic Colorectal Cancer at ESMO 2022
Published: July 4, 2022 | Tags: Seagen, Tukysa, tucatinib, Trastuzumab, HER2-Positive, Metastatic Colorectal Cancer, Clinical Trial, P-II, MOUNTAINEER Trial, ESMO, 2022
AstraZeneca Presents Results of Imfinzi in P-III (HIMALAYA) and (TOPAZ-1) Trial for Liver and Biliary Tract Cancer at EASL 2022 and ESMO World GI 2022
Published: July 4, 2022 | Tags: AstraZeneca, Imfinzi, Liver, Biliary Tract Cancer, Clinical Trial, P-III, HIMALAYA, TOPAZ-1 Trial, EASL, 2022, ESMO, World GI, 2022
Related Post: PharmaShots Weekly Snapshots (June 27 – July 01, 2022)
